All sponsors

Galderma R&D $GALD.SW

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS6
PHASE 3 / 2-33
RECRUITING3
READOUTS ≤12 MONTHS3
Open Galderma R&D on the live radar map → 📅 $GALD.SW readout calendar (.ics)
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
Nemolizumab
NCT04204616
P3Active, not recruitingPrurigo Nodularis5002026-10-26 (+51 mo)
CPUO
NCT07074977
P2Active, not recruitingChronic Pruritus of Unknown Origin502026-12 (+3 mo)
AKLIEF
NCT07186413
P3Active, not recruitingAcne Vulgaris5612026-12-31
Nemolizumab 30 mg
NCT07762833
P3RecruitingAtopic Dermatitis2402027-10-28
Nemolizumab
NCT07047690
P2RecruitingSystemic Sclerosis1622028-05-28 (+22 mo)
NemoBaby
NCT07660835
P2RecruitingModerate-to-Severe Atopic Dermatitis352028-07-15